Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study.

Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR.

Neurology. 2010 Apr 13;74(15):1208-16. doi: 10.1212/WNL.0b013e3181d8c20a.

2.

Striatal and white matter predictors of estimated diagnosis for Huntington disease.

Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, Nance M; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG)..

Brain Res Bull. 2010 May 31;82(3-4):201-7. doi: 10.1016/j.brainresbull.2010.04.003.

3.

Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.

Hua X, Lee S, Hibar DP, Yanovsky I, Leow AD, Toga AW, Jack CR Jr, Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2010 May 15;51(1):63-75. doi: 10.1016/j.neuroimage.2010.01.104.

4.

Biomarkers to predict and track diseases.

Paulsen JS.

Lancet Neurol. 2009 Sep;8(9):776-7. doi: 10.1016/S1474-4422(09)70203-0. No abstract available.

5.

Therapeutic interventions for disease progression in Huntington's disease.

Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006455. doi: 10.1002/14651858.CD006455.pub2. Review.

PMID:
19588392
6.

CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Langbehn DR, Hayden MR, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group..

Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408. doi: 10.1002/ajmg.b.30992. Review.

7.

Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease.

Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC.

Neuroimage. 2009 Oct 1;47(4):1659-65. doi: 10.1016/j.neuroimage.2009.06.003.

PMID:
19523522
8.

Small molecule drug discovery for Huntington's Disease.

Fecke W, Gianfriddo M, Gaviraghi G, Terstappen GC, Heitz F.

Drug Discov Today. 2009 May;14(9-10):453-64. doi: 10.1016/j.drudis.2009.02.006. Review.

PMID:
19429504
9.

Longitudinal diffusion tensor imaging in Huntington's Disease.

Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH.

Exp Neurol. 2009 Apr;216(2):525-9. doi: 10.1016/j.expneurol.2008.12.026.

PMID:
19320010
10.

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.

Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, Ciammola A, Colonnese C, Frati L, Ciarmiello A.

CNS Neurosci Ther. 2009 Winter;15(1):1-11. doi: 10.1111/j.1755-5949.2008.00068.x.

PMID:
19228174
11.

The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.

Gil JM, Rego AC.

Brain Res Rev. 2009 Mar;59(2):410-31. doi: 10.1016/j.brainresrev.2008.12.001. Review.

PMID:
19118572
12.

Bayesian analysis of neuroimaging data in FSL.

Woolrich MW, Jbabdi S, Patenaude B, Chappell M, Makni S, Behrens T, Beckmann C, Jenkinson M, Smith SM.

Neuroimage. 2009 Mar;45(1 Suppl):S173-86. doi: 10.1016/j.neuroimage.2008.10.055.

PMID:
19059349
13.

Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.

Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF.

Brain Res Rev. 2008 Jun;58(1):209-25. doi: 10.1016/j.brainresrev.2008.04.001. Review.

PMID:
18486229
14.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

15.

Morphology of the cerebral cortex in preclinical Huntington's disease.

Nopoulos P, Magnotta VA, Mikos A, Paulson H, Andreasen NC, Paulsen JS.

Am J Psychiatry. 2007 Sep;164(9):1428-34.

PMID:
17728429
16.

Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.

Aylward EH.

Brain Res Bull. 2007 Apr 30;72(2-3):152-8. Review.

PMID:
17352939
17.

Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F.

J Nucl Med. 2006 Feb;47(2):215-22.

18.

Pharmaceutical, cellular and genetic therapies for Huntington's disease.

Handley OJ, Naji JJ, Dunnett SB, Rosser AE.

Clin Sci (Lond). 2006 Jan;110(1):73-88. Review.

PMID:
16336206
19.

Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.

Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B.

Neurology. 2005 Sep 13;65(5):745-7.

PMID:
16157910
20.

Brain structure in preclinical Huntington's disease.

Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC.

Biol Psychiatry. 2006 Jan 1;59(1):57-63.

PMID:
16112655
Items per page

Supplemental Content

Support Center